Showing results (1431-1440 of 1,835) with videos related to

Sort By:
Pageof 184
Signal Transduction and Targeted Therapy|September 19, 2023
Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphomaWeiping Liu, Ningjing Lin, Xinqin Feng, et al.
Signal Transduction and Targeted Therapy|September 14, 2023
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virusEntao Li, Xiaoping Guo, Dongxiang Hong, et al.
Signal Transduction and Targeted Therapy|August 29, 2023
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potentialMinlan Yuan, Biao Yang, Gerson Rothschild, et al.
Signal Transduction and Targeted Therapy|September 5, 2023
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trialsXin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy|September 5, 2023
Mitochondrial dynamics in health and disease: mechanisms and potential targetsWen Chen, Huakan Zhao, Yongsheng Li
Signal Transduction and Targeted Therapy|September 12, 2023
RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translationTing Zhang, Huiling Zheng, Danjuan Lu, et al.
Signal Transduction and Targeted Therapy|August 10, 2023
Chronic pulmonary bacterial infection facilitates breast cancer lung metastasis by recruiting tumor-promoting MHCIIhi neutrophilsTeng Ma, Yu Tang, Taolin Wang, et al.
Signal Transduction and Targeted Therapy|August 6, 2023
Extracellular RNAs-TLR3 signaling contributes to cognitive impairment after chronic neuropathic pain in miceXueying Zhang, Rui Gao, Changteng Zhang, et al.
Signal Transduction and Targeted Therapy|August 6, 2023
Nanomedicine in cancer therapyDahua Fan, Yongkai Cao, Meiqun Cao, et al.
Signal Transduction and Targeted Therapy|August 13, 2023
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialYunpeng Yang, Jie Min, Nong Yang, et al.
Pageof 184